Update on breast implants and the risk of anaplastic large cell lymphoma

The Therapeutic Goods Administration (TGA) recently published the outcome from its review of breast implants and breast tissue expanders in Australia. The evidence available at present suggests that breast implant associated anaplastic large cell lymphoma (BIA-ALCL) is more likely to occur in implants with a greater surface area and roughness (macro-textured). Therefore, some breast implant devices have been suspended, and the full list is available on the TGA website.

The suspensions do not affect the supply of the smooth implants available and to date there are no known cases of BIA-ALCL in Australia where only smooth devices have been implanted.

There are new conditions associated with use of breast implant devices. These include making patients aware of the warning and risks associated with the product used, and the risk of BIA-ALCL, as well as enhanced reporting of adverse events and timely reporting of all cases of BIA-ALCL to the TGA.

Information for patients on the TGA website now includes an informative Q and A video.

Not yet subscribed to receive our medico-legal blog? Scroll down to subscribe and stay connected.

This blog contains general information only. We recommend you contact your medical defence organisation or insurer when you require specific advice in relation to medico-legal matters.